TrialJournal for immunotherapy of cancer2025

Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial.

Maliazurina B Saad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.